 Altimmune is changing its focus from infectious diseases towards metabolic and liver diseases. The company is leaning on Pemvidutide for obesity, NAFLD, and NASH. So far, the dual GLP-1glucagon receptor agonist has produced impressive results in addressing metabolic dysfunction, which evolves into chronic diseases and comorbidity. 